Baseline patient characteristics
| Patient no | Age | Sex | Years since diagnosis | PC20 (mg/ml) | FEV1 (% pred) | Allergies | β2-Receptor polymorphisms | |
| arg16gly | gln27glu | |||||||
| 1 | 20 | M | 13 | 4.0 | 91.9 | P, D, A | Gly/Gly | Gln/Gln |
| 2 | 19 | M | 5 | 3.8 | 81.8 | D, A | Gly/Gly | Glu/Glu |
| 3 | 20 | M | 8 | 4.5 | 105.7 | P, D | Arg/Gly | Gln/Gln |
| 4 | 18 | M | 5 | 0.2 | 84.2 | P | Arg/Gly | Gln/Glu |
| 5 | 36 | F | 5 | 5.0 | 103.6 | P, D, A | Gly/Gly | Gln/Glu |
| 6 | 19 | F | 11 | 3.3 | 102.2 | P, D, A | Gly/Gly | Gln/Gln |
| 7 | 39 | F | 6 | 4.2 | 86.8 | P, A | Arg/Arg | Gln/Gln |
| 8 | 20 | F | 10 | 3.8 | 109.1 | P, D | Arg/Gly | Gln/Glu |
| 9 | 42 | F | 10 | 5.5 | 115.3 | P | Arg/Gly | Gln/Glu |
| 10 | 44 | M | 8 | 0.4 | 82.5 | D | Arg/Gly | Gln/Glu |
| 11 | 18 | M | 3 | 2.8 | 95.8 | P | Gly/Gly | Glu/Glu |
| 12 | 29 | M | 3 | 5.5 | 88.7 | P, A | Gly/Gly | Glu/Glu |
| 13 | 18 | M | 6 | 0.8 | 89.9 | D, A | Arg/Gly | Gln/Gln |
| 14 | 38 | M | 28 | 0.8 | 92.0 | P, D | Arg/Gly | Gln/Glu |
| 15 | 26 | F | 10 | 1.5 | 93.2 | P, D | Arg/Gly | Gln/Glu |
| 16 | 19 | M | 10 | 1.4 | 97.3 | P, D, A | Gly/Gly | Glu/Glu |
| 17 | 19 | F | 8 | 8.0 | 87.0 | P, D, A | Arg/Gly | Gln/Glu |
| 18 | 20 | F | 15 | 2.7 | 106.0 | P | Arg/Gly | Gln/Glu |
| Median | 20 | 8 | 3.6 | 92.6 | ||||
A, animal hair; Arg, arginine; D, house dust mite; F, female; FEV1, forced expiratory volume in 1 s as a percentage of the predicted value (% pred); Gln, glutamine; Glu, glutamic acid; Gly, glycine; M, male; P, pollen; PC20, provocative concentration of histamine causing a 20% fall in FEV1.